Compare Entegris Inc (ENTG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs TransMedics Group Inc — how do they compare? Entegris Inc trades at $134.44 (market cap $21.12B), while TransMedics Group Inc trades at $76.43 (market cap $2.61B). The key difference: Entegris Inc is far larger — about 8.1× TransMedics Group Inc's market cap, and Entegris Inc pays a 0.29% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ENTG | TMDX | |
|---|---|---|
Market Cap | $21.12B | $2.61B |
Sector | Technology | Technology |
52-Week High | $184.00 | $150.42 |
52-Week Low | $68.80 | $61.99 |
Enterprise Value | $24.44B | $3.01B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $140.63, up 3.2% on the day, with a bearish technical signal and premium valuation metrics. The company reported strong Q1 2026 earnings, beating estimates, and maintains a solid cash flow position. Recent news highlights a quarterly dividend declaration and a non-exclusive cross-licensing agreement for EUV lithography technology.
The outlook is mixed: Wall Street analysts maintain a bullish consensus with a $178.40 price target (26.9% upside), citing AI-driven semiconductor demand as a catalyst. However, risks include elevated valuation multiples, competitive pressures in the semiconductor materials sector, and execution challenges in maintaining recent earnings momentum.
TransMedics (TMDX) trades at $77.46, up 3.85% on the day, with a bullish technical signal and strong analyst support. The company reported robust profitability with a 27.04% net margin and 45.22% ROE, though recent Q1 2026 earnings missed expectations. Strategic expansion into Europe via the PAD Aviation investment aims to strengthen its organ transplant logistics network, a key competitive advantage. The stock's valuation metrics include a P/E of 17.25 and P/S of 4.7.
The outlook remains positive with a $108.71 consensus price target (40% upside), supported by 9 buy ratings. Key opportunities include market share gains and European expansion, while risks involve margin pressure from investments and competitive threats. Execution on growth initiatives amid decelerating revenue growth will be critical for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
